TCON OTC
TRACON Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
1Y: -94.8%
3Y: -99.9%
5Y: -99.9%
$0.03
Last traded 2025-07-16 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$12M
+0.0% ▲
5Y CAGR: +32.0%
Gross Profit
$12M
+75293.8% ▲
Operating Income
-$7M
+75.3% ▲
Net Income
-$4M
+87.8% ▲
EPS (Diluted)
$-2.19
+92.2% ▲
EBITDA
-$7M
+75.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $346K | $0 | $12M |
| YoY Growth | -100.0% | +0.0% | +0.0% | -100.0% | +0.0% |
| Cost of Revenue | $22K | $12K | $14K | $16K | $14K |
| Gross Profit | -$22K | -$12K | $332K | -$16K | $12M |
| Gross Margin | — | — | 96.0% | — | 99.9% |
| R&D Expenses | $15M | $8M | $11M | $14M | $12M |
| SG&A Expenses | $8M | $8M | $18M | $14M | $7M |
| Operating Expenses | $22M | $16M | $29M | $28M | $19M |
| Operating Income | -$22M | -$16M | -$28M | -$28M | -$7M |
| Operating Margin | — | — | -8192.8% | — | -57.3% |
| Interest Expense | $386K | $545K | $318K | $994K | $7M |
| Income Before Tax | -$23M | -$17M | -$29M | -$29M | -$4M |
| Tax Expense | -$16K | $551K | $0 | $177K | $0 |
| Net Income | -$23M | -$17M | -$29M | -$29M | -$4M |
| Net Margin | — | — | -8302.3% | — | -29.8% |
| EPS (Diluted) | $-149.35 | $-38.57 | $-33.30 | $-28.02 | $-2.19 |
| EBITDA | -$22M | -$16M | -$28M | -$28M | -$7M |
| Shares Outstanding | 151715 | 449207 | 862632 | 1M | 2M |